SCHOOL OF MEDICINE  |  PITT HOME  |  FIND PEOPLE  |  FIND A DOCTOR AT UPMC

Department of Medicine

Department of Medicine

 Division of Infectious Diseases

[Return To Index page]
photo Sharon A. Riddler, MD

Director, Clinical Research, Infectious Diseases Division

Co-Principal Investigator, Pitt-Ohio State Clinical Trials Unit

Member, AIDS Clinical Trials Group (ACTG) Executive Committee

Email: riddler@dom.pitt.edu

Phone: 412-383-1675

Contact
Office: Falk Medical Bldg
3601 Fifth Ave., 7th Floor
Pittsburgh, PA 15213
 
Phone: 412-383-1675
Fax: 412-647-7951
E-mail: riddler@dom.pitt.edu
Administrative Assistant:
Patricia Paulson
Address: Keystone Bldg.
3520 Fifth Avenue, 5th Fl
Pittsburgh, PA 15213
Email: ppaulson@pitt.edu
Phone: 412-383-1675
Fax: 412-383-2900
Education and Training
Education
BS, Marquette University, Milwaukee, WI, 1982
MD, Medical College of Wisconsin, Milwaukee, WI, 1986
MPH Epidemiology, University of Pittsburgh, 2002
Training
Internship, University of Missouri, Kansas City, MO, 1987
Residency Training, University of Missouri, Kansas City, MO, 1990
Infectious Diseases Fellowship, University of Pittsburgh, Pittsburgh, PA, 1994
Research Interest
Dr. Riddler has more than 20 years of experience in clinical research funded by the NIH and industry. She is interested in all aspects of the clinical research process, including protocol development, implementation, and analysis of results. She is the Co-PI of the NIH/DAIDS-funded Pitt-OSU HIV/AIDS Clinical Trials Unit and Site Leader for the University of Pittsburgh Clinical Research Site (affiliated with both the AIDS Clinical Trials Group (ACTG) and the Microbicide Trials Network (MTN)). Dr. Riddler is a Protocol Physician for the Microbicide Trials Network. She has been Chair or Co-Chair for several network studies in the ACTG (A5115, A5142, A5276s, and A5342) and MTN (MTN-015 and MTN-0038). Local clinical trials have focused on immune-based therapies for chronic HIV infection. She is currently the Co-PI for an ongoing U-01-funded Phase I study of dipyridamole for immune activation in HIV-infected participants. Additionally, she was the clinical PI and IND sponsor for two completed studies of dendritic cell-based therapeutic HIV vaccination. Dr. Riddler's group collaborates widely across the University of Pittsburgh to accomplish state-of-the-art clinical trials.
Clinical Interest
Dr. Riddler has cared for patients with HIV infection since 1992. She provides outpatient primary and specialty care to a panel of approximately 200 HIV-infected patients in the Pittsburgh AIDS Center for Treatment.
Educational Interest
Dr. Riddler participates in clinical education of ID fellows and Internal Medicine residents in the HIV clinic.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW. Class-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142. N Engl J Med. 2008; 358: 2095-106.
Mirembe BG, Kelly CW, Mgodi N, Greenspan S, Dai JY, Mayo A, Piper J, Akello CA, Kiweewa FM ,, Magure T, Nakabiito C, Marazzo JM, Chirenje MZ,, Riddler SA. Bone mineral density changes among young, healthy African women receiving oral tenofovir for HIV pre-exposure prophylaxis. J Acquir Immune Defic,. 2016; 71(3): 287-94.
Riddler SA, Aga E, Bosch RJ, Bastow B, Bedison M, Vagratian D, Vaida F, Eron JJ, Gandhi RT,, Mellors JW; ACTG A5276s Protocol Team. Continued slow decay of residual plasma viremia level in HIV-1-infected adults receiving long term antiretroviral therapy. J Infect Dis. 2016; 213(4): 556-60.
Macatangay BJ, Riddler SA, Wheeler ND, Spindler J, Lawani M, Hong F, Buffo MJ, Whiteside TL,, Kearney MF, Mellors JW, Rinaldo CR. Therapeutic vaccination with dendritic cells loaded with autologous HIV Type 1-infected apoptotic cells. J Infect Dis. 2016; 213: 556-60.
Sponsored Research/Activities
Title: A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Role: Principal Investigator
Funding Agency: Gilead Sciences, Inc
Grant Number: DRUG
Start Year: 2015
End Year: 2016
Title: REPRIEVE A5332 and A5333s Protocol Funds
Role: Principal Investigator
Funding Agency: Massachusetts General Hospital/National Heart, Lung, & Blood Institute
Grant Number: U01 HL123336
Start Year: 2014
End Year: 2016
Title: Aids Clinical Trial Group: Core Funding
Role: Principal Investigator
Funding Agency: Brigham and Women's Hospital, Inc./National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI068636
Start Year: 2014
End Year: 2016
Title: LOC: Microbicides Trials Network
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI068633
Start Year: 2014
End Year: 2016
Title: AIDS Clinical Trials Group: Executive Committee Member
Role: Principal Investigator
Funding Agency: Brigham and Women's Hospital, Inc./National Institute of Health
Grant Number: UM1 AI068636
Start Year: 2014
End Year: 2016
Title: Dipyridamole as a Modulator of HIV-1 Inflammation by Adenosine Regulation
Role: Co-Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: U01 AI1110410
Start Year: 2014
End Year: 2018
Title: Pitt-Ohio State - Georgetown Clinical Trials Unit
Role: Co-Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI069494
Start Year: 2013
End Year: 2020
Title: Leadership Operations Center (LOC): Microbicide Trials Network MTN 030 Protocol Funds
Role: Co-Investigator
Funding Agency: Magee Womens Hospital
Grant Number: UM1 AI068633
Start Year: 2016
End Year: 2017
Title: Combined Immunologic Approaches to Cure HIV-1 (Clinical SRS)
Role: Co-Investigator
Funding Agency: Beth Israel Deaconess
Grant Number: UM1 AI126603
Start Year: 2016
End Year: 2017
Title: Combined Immunologic Approaches to Cure HIV-1 (CAB)
Role: Co-Investigator
Funding Agency: Beth Israel Deaconess
Grant Number: UM1 AI126603
Start Year: 2016
End Year: 2017
Title: Feasibility of short-Term PrEP Uptake for MSM with Episodic High-Risk for HIV
Role: Co-Investigator
Funding Agency: National Institute of Mental Health
Grant Number: R34 MH104083
Start Year: 2015
End Year: 2017
Title: Leadership Operations Center (LOC): Microbicide Trials Network MTN 029 Year 10 Protocol Funds
Role: Co-Investigator
Funding Agency: Magee Womens Research Institute and Foundation
Grant Number: UM1 AI068633
Start Year: 2015
End Year: 2017
Title: Microbicide Trials Network Virology Core
Role: Co-Investigator
Funding Agency: Magee Womens Hospital
Grant Number: UM1 AI068633
Start Year: 2006
End Year: 2017